Executive Summary Dupixent (dupilumab) is one of the most commercially successful biologics in history, generating over $14.9 billion in global […]
Merck made $29.5 billion from a single drug last year. That drug, Keytruda, loses its primary patent in 2028. Read
The $236 Billion Cliff: How Pharma Loses Its Blockbusters—and What Replaces Them Read Post »
The Molecular Reality: Why Biosimilars Cannot Be Generics The entire strategic, regulatory, and commercial architecture around biosimilars flows from one
A deep-dive reference for pharma IP teams, R&D leads, and institutional investors on the science, strategy, and commercial mechanics of
Get fresh news and insights, drug patent expirations & more…
